In our in vitro studies, the Rho/MRTF pathway inhibitor CCG-222740 suppressed stellate cell activation and subsequent production of pro-fibrotic ECM components by cancer-associated fibroblasts, without total elimination of these cells. The gene discussed is RHO; the disease is cancer.